These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9582060)

  • 1. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 2. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 3. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 5. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 6. UK firms buy into drug design skills of US start-ups.
    Nature; 1995 Feb; 373(6513):372. PubMed ID: 7830777
    [No Abstract]   [Full Text] [Related]  

  • 7. UK biotech smashes financing record.
    Nat Biotechnol; 2015 Sep; 33(9):889. PubMed ID: 26348941
    [No Abstract]   [Full Text] [Related]  

  • 8. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech industry faces new bottleneck.
    Garber K
    Nat Biotechnol; 2001 Mar; 19(3):184-5. PubMed ID: 11231516
    [No Abstract]   [Full Text] [Related]  

  • 10. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 12. Chief to leave troubled British biotech.
    Masood E
    Nature; 1998 May; 393(6683):299. PubMed ID: 9620789
    [No Abstract]   [Full Text] [Related]  

  • 13. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 14. Investor malaise stalks UK, European biotech.
    Mitchell P
    Nat Biotechnol; 2008 Mar; 26(3):256-7. PubMed ID: 18327222
    [No Abstract]   [Full Text] [Related]  

  • 15. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 16. Corporate venture capital and Cambridge.
    McCammon MG; Pio E; Barakat S; Vyakarnam S
    Nat Biotechnol; 2014 Oct; 32(10):975-8. PubMed ID: 25299912
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 18. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 19. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 20. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.